share_log

PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops From Its Proprietary OPC Platform at ARVO 2024

PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops From Its Proprietary OPC Platform at ARVO 2024

PharmAbcine的美国子公司Wincal Biopharm在2024年ARVO上公布了其专有OPC平台滴眼液的临床前数据
PR Newswire ·  05/23 08:51
  • Presentation at ARVO 2024 gained attention as Eylea (aflibercept) eye drops demonstrated similar efficacy to intravitreal injections in animal studies.
  • 在动物研究中,Eylea(aflibercept)滴眼液显示出与玻璃体内注射相似的功效,因此在ARVO 2024上的演示引起了人们的关注。

DAEJEON, South Korea , May 22, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced that its U.S. subsidiary, Wincal Biopharm, Inc. ("WincalBio"), gained agreat attention at the world's largest ophthalmology conference, Association for Research in Vision and Ophthalmology 2024 (ARVO 2024), when they presented the preclinical data of the eye drop formulation.

韩国大田,2024 年 5 月 22 日 /PRNewswire/ — PharmabCine, Inc.(“PharmabCine” 或 “公司”)(KOSDAQ: 208340)是一家处于临床阶段的上市公司,开发用于治疗未满足的医疗需求的下一代疗法。该公司宣布,其美国子公司Wincal Biopharm, Inc.(“WincalBio”)在全球最大的眼科会议——2024年视觉与眼科研究协会(ARVO 2024)上获得了高度关注,当时他们展示了眼药水配方的临床前数据。

WincalBio revealed that currently marketed therapeutic antibodies can be delivered within the eyes using their proprietary Ocular Penetration Carrier (OPC) screening platform, as shown by animal studies. This innovation suggests that non-invasive eye drops could potentially replace traditional intravitreal injection methods for treating eye diseases.

WincalBio透露,动物研究表明,目前上市的治疗性抗体可以使用其专有的眼穿透载体(OPC)筛查平台在眼内输送。这项创新表明,非侵入性眼药水有可能取代传统的玻璃体内注射方法来治疗眼部疾病。

The OPC screening platform was developed to identify antibody-carrier complexes capable of delivering therapeutic agents into the back of the eye, such as the vitreous, retina, and choroid, without relying on needle injections. This allows patients to administer treatment conveniently at home using eye drops. The key to this technology is finding a matching carrier to each antibody to facilitate drug delivery inside the eye.

开发OPC筛查平台的目的是识别能够在不依赖针头注射的情况下将治疗药物输送到眼后(例如玻璃体、视网膜和脉络膜)的抗体载体复合物。这使患者可以在家中使用眼药水方便地进行治疗。这项技术的关键是为每种抗体找到匹配的载体,以促进药物在眼内输送。

At ARVO 2024, WincalBio gave an oral presentation that their OPC screening platform enabled the delivery of the anti-VEGF treatments, Eylea (aflibercept) and Beovu (brolucizumab), as eye drops. In a laser-induced choroid neovascularization (CNV) mouse model, the OPC eye drop formulations demonstrated significant reduction in lesion size and vascular leakage, showing similar efficacy to the intravitreal injections. This breakthrough received huge interest and enthusiasm from the meeting participants.

在2024年的ARVO上,WincalBio做了口头陈述,称他们的OPC筛查平台使抗血管内皮生长因子疗法Eylea(aflibercept)和Beovu(brolucizumab)作为滴眼剂提供抗血管内皮生长因子疗法。在激光诱导脉络膜新生血管(CNV)小鼠模型中,OPC滴眼液配方显示病变大小和血管渗漏显著减少,表现出与玻璃体内注射相似的疗效。这一突破引起了与会者的极大兴趣和热情。

Dr. Venice Chiueh, Project leader and Director at WincalBio, stated that "Developing eye drop formulations is crucial for enhancing patient convenience and reducing the patient's reluctance to receiving treatment. We are committed to achieving successful outcomes not only in upcoming primate efficacy studies but also in clinical trials."

WincalBio项目负责人兼董事Venice Chiueh博士表示:“开发眼药水配方对于提高患者的便利性和减少患者不愿接受治疗的情绪至关重要。我们不仅致力于在即将到来的灵长类动物疗效研究中取得成功结果,还致力于在临床试验中取得成功结果。”

Dr. TaeWeon Lee, Chief Scientific Officer at WincalBio, added, "These research results are expected to positively impact VC investment opportunities as well as corporate partnerships with biopharma companies with intravitreal therapeutics or planned launch of biosimilars. Our aim is to extend this innovative technology beyond the anti-VEGFantibodies to various eye disease treatments, allowing patients to receive moreconvenient and accessible care."

WincalBio首席科学官TaeWeon Lee博士补充说:“这些研究结果预计将对风险投资机会以及与采用玻璃体内疗法或计划推出的生物仿制药的生物制药公司的企业合作伙伴关系产生积极影响。我们的目标是将这项创新技术从抗血管内皮生长因子抗体扩展到各种眼病治疗方法,让患者获得更便捷和更容易获得的护理。”

SOURCE PharmAbcine

来源 PharmabCine

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发